In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 126 to 150 of 349

Sort by

Guidance programme: Technology appraisal guidanceRemove Guidance programme: Technology appraisal guidance filter

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Finerenone for treating heart failure with preserved or mildly reduced ejection fraction [ID6514]	Technology appraisal guidance	4 June 2026
Fordadistrogene movaparvovec for treating Duchenne muscular dystrophy [ID6133]	Technology appraisal guidance	TBC
Ganaxolone for adjunctive treatment of epilepsy associated with tuberous sclerosis complex with CDKL5 deficiency disorder [TSID12126]	Technology appraisal guidance	TBC
Gantenerumab for treating early Alzheimer's disease [ID6142]	Technology appraisal guidance	TBC
Gefurulimab for treating antibody-positive generalised myasthenia gravis [TSID12256]	Technology appraisal guidance	TBC
Giredestrant with everolimus for treating oestrogen-receptor positive HER2-negative advanced breast cancer after cyclin-dependent kinase 4 and 6 inhibitor and endocrine treatment [ID6576]	Technology appraisal guidance	TBC
Giredestrant with palbociclib for untreated oestrogen-receptor positive HER2-negative advanced breast cancer [ID5072]	Technology appraisal guidance	TBC
Giroctocogene fitelparvovec for treating moderately severe to severe haemophilia A [ID6312]	Technology appraisal guidance	TBC
Givinostat for treating Duchenne muscular dystrophy in people 6 years and over [ID6323]	Technology appraisal guidance	TBC
Glycopyrronium bromide cream for treating severe primary axillary hyperhidrosis [ID6487]	Technology appraisal guidance	11 March 2026
Govorestat for treating classic galactosemia in people 2 to 65 years [TSID12071]	Technology appraisal guidance	TBC
Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia [ID1627]	Technology appraisal guidance	TBC
Hydromethylthionine mesylate for treating mild cognitive impairment or mild or moderate dementia caused by Alzheimer's disease [ID6343]	Technology appraisal guidance	TBC
Ianalumab for treating active Sjogren's syndrome [ID6634]	Technology appraisal guidance	TBC
Ibrutinib for treating relapsed or refractory follicular lymphoma [ID1251]	Technology appraisal guidance	TBC
Ibrutinib with R-CHOP for untreated mantle cell lymphoma when an autologous stem cell transplant is suitable [ID6596]	Technology appraisal guidance	TBC
Iclepertin for treating cognitive impairment associated with schizophrenia [ID6483]	Technology appraisal guidance	TBC
Icotrokinra for treating moderate to severe plaque psoriasis in people 12 years and over [ID6579]	Technology appraisal guidance	TBC
Imetelstat for treating relapsed or refractory transfusion-dependent myelodysplastic syndromes [ID3922]	Technology appraisal guidance	TBC
Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy [ID6373]	Technology appraisal guidance	TBC
Inavolisib with fulvestrant for treating recurrent hormone receptor-positive HER2-negative PIK3CA-mutated locally advanced or metastatic breast cancer after a CDK 4-6 inhibitor [ID6650]	Technology appraisal guidance	TBC
Inavolisib with palbociclib and fulvestrant for treating recurrent hormone receptor-positive HER2-negative PIK3CA-positive advanced breast cancer after adjuvant endocrine treatment [ID6425]	Technology appraisal guidance	12 June 2026
Inclacumab for preventing recurrent vaso-occlusive crises in sickle cell disease in people 16 years and over [ID6551]	Technology appraisal guidance	TBC
Infigratinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement [ID3992]	Technology appraisal guidance	TBC
Inhaled treprostinil for treating pulmonary hypertension with interstitial lung disease [ID6459]	Technology appraisal guidance	21 May 2026

Results per page

10
25
50
All